Screener
Kyverna Therapeutics, Inc. KYTX Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued license expense – related party | 3,750 | 3,750 |
| Other accrued expenses and current liabilities | 9,222 | 13,472 |
| Operating lease liabilities, short-term portion | 1,764 | 3,662 |
| Finance lease liabilities, short-term portion | 221 | 307 |
| Total current liabilities | 29,674 | 36,487 |
| Operating lease liabilities, net of short-term portion | 6,958 | 320 |
| Term loan | 24,812 | 24,743 |
| Total liabilities | 61,444 | 61,550 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s current debt?
- Kyverna Therapeutics, Inc. (KYTX) reported current debt of $221K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s current debt changed year-over-year?
- Kyverna Therapeutics, Inc.'s current debt decreased by 56.4% year-over-year, from $507K to $221K.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s current debt?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s current debt has grown at a -43.3% compound annual growth rate (CAGR), from $956K to $307K.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Kyverna Therapeutics, Inc.'s current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude